Evidence-based protocols for switching between rapamycin (sirolimus) and other mTOR inhibitors or immunosuppressants, including everolimus, tacrolimus, and off-label longevity regimens.
A guide to Adderall XR (mixed amphetamine salts) regulatory status worldwide, covering FDA approval history, DEA scheduling, EMA classification, and current label safety information.
FDA prescribing info for Adderall XR warns of sudden death in patients with pre-existing cardiac abnormalities. Boxed warning covers abuse. Schedule II.
Praluent (alirocumab) was FDA approved July 24, 2015, and has been on the market over 9 years, with a cardiovascular indication added in April 2019.
Regulatory overview of Praluent (alirocumab): FDA approval history, EMA authorization, the ODYSSEY OUTCOMES cardiovascular indication, label changes, and what remains unverified in secondary summaries of this history.
A comprehensive review of FDA label changes for alprostadil (Caverject, MUSE, Edex) from 2020 through 2026, covering safety revisions, post-market surveillance data, and clinical guidance for prescribers.
A complete timeline of AndroGel (testosterone gel 1%) FDA label revisions from 2020 through 2026, covering cardiovascular warnings, REMS modifications, transfer risk language, and post-market surveillance findings.
A clinical review of AndroGel's regulatory history, patent disputes, Paragraph IV litigation, FDA label changes, and cardiovascular safety controversies from approval through post-market surveillance.
AOD-9604 has never received FDA approval. Review the full regulatory timeline, failed clinical trials, FDA compounding restrictions, and what this means for patients considering this peptide.
An evidence-based review of AOD-9604 (HGH fragment 176-191) safety signals in the FDA Adverse Event Reporting System, regulatory status, and what clinicians should know about post-market surveillance for this compounded peptide.
A clinical review of Armour Thyroid's FDA regulatory history, compounding legal status under sections 503A and 503B, label requirements, and safety data for natural desiccated thyroid.
How the FDA and EMA differ in their regulatory handling of BPC-157 pentadecapeptide, including compounding status, clinical trial requirements, and safety oversight.
No new black box warning, but tadalafil's label added stronger hearing loss and NAION warnings, revised renal dosing, and SGLT2 interaction data.
Complete history of Cialis (tadalafil) legal battles, patent disputes, FDA approval milestones, and regulatory actions from 2003 through generic entry.
CJC-1295 (modified GRF 1-29) has never received FDA or EMA approval. Learn its current regulatory classification, compounding pharmacy status, and safety profile across major jurisdictions.
Farxiga won FDA approval January 8, 2014 for type 2 diabetes, then added heart failure (2020) and chronic kidney disease (2021) indications.
Complete regulatory overview of denosumab (Prolia/Xgeva) covering FDA approval history, EMA authorization, boxed warning additions, REMS requirements, and global post-market surveillance findings.
The FDA Prolia (denosumab) label, last revised March 2025, warns that stopping treatment raises fracture risk, including multiple vertebral fractures.
A clinical review of Trulicity's regulatory timeline, patent disputes, Paragraph IV litigation, and post-market safety actions that shape dulaglutide access in 2026.
A clinical review of dutasteride's regulatory history, current FDA label, post-market safety surveillance, and emerging next-generation 5-alpha reductase inhibitor candidates in development.
Every FDA label change for Jardiance (empagliflozin) from 2020 through 2026, including new indications for heart failure, chronic kidney disease, and updated safety warnings.
A complete analysis of Jardiance (empagliflozin) legal disputes, patent challenges, FDA approval history, label expansions, and post-market safety actions from 2014 through 2026.
A detailed review of enclomiphene citrate's current FDA approval status, compounding legality under 503A and 503B, safety considerations, and what the regulatory picture means for patients and prescribers.
A detailed comparison of how the FDA and EMA have handled enclomiphene citrate, including its failed NDA, compounding pharmacy access, and current regulatory status for male hypogonadism.
A clinical review of enclomiphene citrate's regulatory trajectory, FDA approval status, phase III trial data, compounding pharmacy access, and emerging next-generation SERM alternatives for male hypogonadism.
Epitalon (Ala-Glu-Asp-Gly) has no FDA or EMA approval. Learn the current regulatory classification in the US, EU, Russia, Australia, and other markets, plus what the science actually shows.
Epitalon (epithalon) has no FDA approval, no active U.S. patent protection, and no completed phase III trials. This article covers the peptide's regulatory status, legal gray areas, and what the clinical evidence actually supports.
A side-by-side comparison of how the FDA and EMA regulate oral estradiol for menopausal hormone therapy, including labeling, safety warnings, and prescribing differences.
A detailed review of oral estradiol post-market safety signals from the FDA Adverse Event Reporting System (FAERS), including venous thromboembolism, cardiovascular events, and hepatic first-pass concerns.
A clinical review of the estradiol transdermal patch pipeline, including FDA-approved products, emerging next-generation delivery systems, updated safety data, and prescribing label details for hormone replacement therapy.
A complete regulatory timeline of ezetimibe (Zetia) from its 2002 FDA approval through IMPROVE-IT outcomes data, generic entry, and current labeling.
A clinical review of finasteride safety signals in the FDA Adverse Event Reporting System (FAERS), including sexual dysfunction, depression, and suicidality reports that prompted label revisions.
A cautious, source-checked look at how the FDA label and REMS program for Addyi (flibanserin) changed between 2020 and 2026, including the alcohol-warning revision and the 2023 REMS modification, with a note on which claims still need primary-source verification.
A clinician-focused review of GHK-Cu (copper tripeptide) regulatory status worldwide, including FDA compounding guidance, EMA classification, and country-by-country legal frameworks for prescribing and importing GHK-Cu.
Leqvio (inclisiran) received FDA approval on December 22, 2021, making it available for roughly three years as the first siRNA therapy targeting PCSK9.
Ipamorelin has never received FDA approval. Review the full regulatory timeline from preclinical development through compounding pharmacy access, clinical trial history, and current FDA enforcement posture.
Complete regulatory timeline of isotretinoin from its 1982 FDA approval through iPLEDGE implementation, generic entry, and ongoing post-market safety surveillance.
A detailed review of isotretinoin (Accutane) safety signals reported to the FDA Adverse Event Reporting System (FAERS), covering psychiatric events, IBD associations, teratogenicity monitoring through iPLEDGE, and what the post-market surveillance data mean for prescribers and patients.
Full FDA approval history of losartan (Cozaar), from its 1995 original approval through generic entry, pediatric labeling, LIFE trial supplemental data, and recall events.
Low-dose naltrexone (LDN) is not FDA-approved at doses below 50 mg. Learn how 503A compounding pharmacies legally prepare LDN, current regulatory status, and the clinical evidence behind off-label prescribing.
A clinical review of low-dose naltrexone (LDN) regulatory status from 2020 through 2026, covering FDA-approved labeling for naltrexone 50 mg, compounding pharmacy oversight under 503A/503B, and emerging safety and efficacy data.
The FDA metformin label recommends measuring vitamin B12 at baseline and periodically, typically every 1 to 2 years, especially with anemia or neuropathy.
Complete FDA approval history of methimazole (Tapazole), including original approval, label updates, safety communications, and post-market surveillance data for hyperthyroidism treatment.
MK-677 (ibutamoren) has never received FDA approval and carries no official drug label. This article covers the 2020-2026 regulatory timeline, FDA enforcement actions, safety data, and what clinicians and patients should know.
A comprehensive review of MK-677 (ibutamoren) regulatory status, FDA history, patent disputes, and legal barriers preventing clinical approval of this growth hormone secretagogue.
A clinical guide to the FDA regulatory status of modafinil (Provigil), its compounding eligibility under federal law, and what prescribers should understand about 503A and 503B pathways.
MOTS-c has no FDA approval and remains an investigational mitochondrial peptide worldwide. Learn its regulatory classification in the US, EU, Australia, and Asia, plus the clinical evidence behind ongoing research.
MOTS-c has no FDA approval and no drug label. This article covers the full regulatory timeline from 2020 to 2026, including FDA peptide enforcement actions, research milestones, and safety data for this mitochondrial-derived peptide.
MOTS-c remains unapproved by the FDA with no IND-stage clinical trials in humans. This article covers the patent disputes, regulatory classification questions, and safety concerns surrounding this mitochondrial-derived peptide.
A clinical review of Mounjaro (tirzepatide) legal battles, patent disputes, FDA approval timeline, label updates, and post-market safety surveillance.
A clinical comparison of how the FDA and EMA regulate oral micronized progesterone (Prometrium/Utrogestan), including labeling differences, boxed warnings, and post-market safety data.
A clinical and regulatory guide to oral minoxidil compounding legality, covering FDA approval history, 503A and 503B pharmacy pathways, Loniten labeling, off-label prescribing for hair loss, and safety data.
A clinical comparison of how the FDA and EMA regulate oral minoxidil for hair loss, including approval history, labeling, off-label prescribing trends, and safety monitoring requirements.
A comprehensive review of oral minoxidil (low-dose) label updates from 2020 through 2026, covering FDA safety communications, off-label dermatologic use, cardiovascular monitoring requirements, and emerging clinical data.
A clinical review of FDA Adverse Event Reporting System (FAERS) data on low-dose oral minoxidil, including cardiovascular signals, pericardial effusion reports, and how prescribers should interpret real-world pharmacovigilance findings.
A clinical review of Ozempic (semaglutide) regulatory history, current FDA label, post-market safety surveillance, and the next-generation GLP-1 pipeline from Novo Nordisk and competitors.
A clinical review of Ozempic (semaglutide) FDA Adverse Event Reporting System signals, label updates, and post-market safety data through 2026.
A clinical comparison of how the FDA and EMA regulate Prometrium (micronized progesterone), including approval history, labeling differences, post-market surveillance, and prescribing implications for HRT.
A clinical review of Prometrium (micronized progesterone) regulatory approvals worldwide, including FDA history, EMA status, Health Canada authorization, label requirements, and post-market safety data.
FDA history of Prometrium (micronized progesterone), current label details, post-market safety data, and emerging next-generation progesterone delivery systems in clinical development.